PALO ALTO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D. has been appointed President and Chief Financial Officer (CFO) of the Company. He recently assumed the role of Principal Financial Officer and will continue to lead the Company’s FP&A and accounting operations.
Brian Stephenson, Ph.D. will depart from the Company for personal reasons. Dr. Stephenson's departure was not the result of a disagreement with the Company on any matters relating to the Company’s operations, policies or practices. Dr. Stephenson will continue to serve as a consultant to the Company.
“It has been an immense privilege to be a part of the BridgeBio team since its inception and to help serve as many patients as possible through our efforts. I’m proud to have helped pioneer a new type of financial model – one that makes possible broad patient service through the application of portfolio theory and use of formal NPV-driven decision-making frameworks. I look forward to seeing the impact BridgeBio will continue to have on the industry and genetic disease patient communities,” said Dr. Stephenson.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit www.bridgebio.com and follow us on LinkedIn, Twitter and Facebook.
BridgeBio Media Contact:
Bubba Murarka, EVP Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
(650)-789-8220
| Last Trade: | US$46.27 |
| Daily Change: | 0.29 0.63 |
| Daily Volume: | 2,394,814 |
| Market Cap: | US$8.790B |
June 30, 2025 June 26, 2025 May 20, 2025 May 13, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
